Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5131617 | 0.85 | BCHE (0.58) | MEN1KMT2ASMN1; SMN2BCHEGAA | |
| SCHEMBL6469030 | 0.84 | KCNH2 (0.56) | MEN1KMT2ABCHEGAAATM | |
| SCHEMBL6471113 | 0.84 | TMEM97 (0.44) | MEN1KMT2ABCHEGAAATM | |
| SCHEMBL6468987 | 0.82 | MEN1 (0.53) | MEN1KMT2AHTTSMN1; SMN2BCHE | |
| SCHEMBL5042778 | 0.81 | TMEM97 (0.63) | MEN1KMT2ABCHEADRB2GAA | |
| SCHEMBL5133519 | 0.79 | CPB2 (0.40) | MEN1KMT2AHTTSMN1; SMN2BCHE | |
| SCHEMBL5132093 | 0.78 | ADRB2 (0.41) | MEN1KMT2AHTTSMN1; SMN2BCHE | |
| SCHEMBL11824647 | 0.78 | BCHE (0.74) | MEN1KMT2AHTTSMN1; SMN2BCHE | |
| SCHEMBL5037248 | 0.77 | MEN1 (0.40) | MEN1KMT2AHTTSMN1; SMN2BCHE | |
| SCHEMBL6470796 | 0.77 | HTT (0.43) | MEN1KMT2AHTTSMN1; SMN2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2005-05-19 | — | — | US | claimed |
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | APP, BACE1, SNCA | MEN1 978/4885KMT2A 2085/4885HTT 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.